MedTrace Logo

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

NCT04312308 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-02-06

No results posted yet for this study

Summary

The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-L1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during atezolizumab treatment.

Conditions

  • Non Small Cell Lung Cancer

Interventions

OTHER

Sample collection

1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression. 2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression) 3\. microbiome Pretreatment stool sample will be collected. (Stool sample is optional) 4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional. 4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-08
Primary Completion
2025-01-26
Completion
2025-01-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312308 on ClinicalTrials.gov